• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Superior Subtractive Solutions for Machining Medtech

    Assembly & Automation Experts Share Thoughts on Medtech Trends

    Power Trip: A Discussion of Custom Medical Electronics

    The MDR Transition: An Opportunity for Design Change?

    Preserve and Protect: Sustainability Initiatives for Medtech Manufacturing
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most-Read Stories This Week—Sept. 23

    Beckman Coulter Helping Labs Comply With Annex 1 Regulation

    FDA Clears MeMed BV Direct From Whole Blood

    Biostrap Debuts Tool to Measure Stress Resilience, Heart Rate Variability

    EndoTheia Announces Positive Study Results for Endoscopic Surgery Device
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Superior Subtractive Solutions for Machining Medtech

    Assembly & Automation Experts Share Thoughts on Medtech Trends

    Power Trip: A Discussion of Custom Medical Electronics

    The MDR Transition: An Opportunity for Design Change?

    Preserve and Protect: Sustainability Initiatives for Medtech Manufacturing
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Medtech’s Most Powerful M&A Drivers

    The Link Between Medtech and Connected Medical Devices

    Is the FTC Partly Responsible for Muted M&A Activity?

    Holistic Risk Management: Navigating the Future’s Uncertainties

    Defining End of Life for Medical Devices
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    NDH Medical Inc.

    Cirtec Medical

    Providence Enterprise USA Inc.

    Medbio LLC

    Arthur G. Russell Co. Inc., The
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    A One-Stop-Shop, Turnkey Solution Is Paramount for Success

    How Additive and Subtractive Manufacturing Are Revolutionizing the Medical Device Industry

    Medical Device Commercialization: It’s What, Not When, to Transfer to Manufacturing

    How In Silico Simulations Can Slash Medical Device Development Risk

    The Top 7 AI Applications Transforming Medical Device Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    NDH Medical Inc.

    Cirtec Medical

    Providence Enterprise USA Inc.

    Medbio LLC

    Arthur G. Russell Co. Inc., The
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    FDA Green Lights First Ever Artificial Iris

    The CustomFlex Artificial Iris is made of thin, foldable medical-grade silicone and is custom-sized and colored.

    FDA Green Lights First Ever Artificial Iris
    The Artificial Iris is the world's first foldable artificial iris, which is used for clinical and aesthetical reconstruction of eyes with complete or partial aniridia. Image courtesy of HumanOptics AG.
    U.S. Food and Drug Administration06.01.18
    The U.S. Food and Drug Administration approved the first stand-alone prosthetic iris in the United States, a surgically implanted device to treat adults and children whose iris (the colored part of the eye around the pupil) is completely missing or damaged due to a congenital condition called aniridia or other damage to the eye.
     
    “Patients with iris defects may experience severe vision problems, as well as dissatisfaction with the appearance of their eye,” said Malvina Eydelman, M.D., director of the Division of Ophthalmic, and Ear, Nose and Throat Devices at the FDA's Center for Devices and Radiological Health. “Today’s approval of the first artificial iris provides a novel method to treat iris defects that reduces sensitivity to bright light and glare. It also improves the cosmetic appearance of the eye in patients with aniridia.”
     
    Congenital aniridia is a rare genetic disorder in which the iris is completely or partially absent. It affects approximately 1 in 50,000 to 100,000 people in the U.S. The iris controls the amount of light entering the eye, and those with aniridia have sensitivity to light and other severe vision problems. In addition to congenital aniridia, the CustomFlex Artificial Iris is indicated to treat iris defects due to other reasons or conditions, such as albinism, traumatic injury or surgical removal due to melanoma.
     
    The CustomFlex Artificial Iris is made of thin, foldable medical-grade silicone and is custom-sized and colored for each individual patient. A surgeon makes a small incision, inserts the device under the incision, unfolds it and smooths out the edges using surgical instruments. The prosthetic iris is held in place by the anatomical structures of the eye or, if needed, by sutures.
    The safety and effectiveness of the CustomFlex Artificial Iris was demonstrated primarily in a non-randomized clinical trial of 389 adult and pediatric patients with aniridia or other iris defects. The study measured patients’ self-reported decrease in severe sensitivity to light and glare post-procedure, health-related quality of life, and satisfaction with the cosmetic improvement or appearance of the prosthesis. More than 70 percent of patients reported significant decreases in light sensitivity and glare as well as an improvement in health-related quality of life following the procedure. In addition, 94 percent of patients were satisfied with the artificial iris’ appearance.
     
    The study found low rates of adverse events associated with the device or the surgical procedure. In the study, complications associated with the use of the CustomFlex Artificial Iris device included: device movement or dislocation, strands of device fiber in the eye, increased intraocular pressure, inflammation of the iris (iritis), adhesion of the iris to the cornea or lens (synechiae) and the need for secondary surgery to reposition, remove or replace the device. Complications associated with the surgical procedure included: increased intraocular pressure, blood leakage in the eye, swelling of the center of the retina (cystoid macular edema), secondary surgery, corneal swelling, iritis, and retinal detachment.
     
    The CustomFlex Artificial Iris is contraindicated, or should not be used, in eyes with any of the following conditions: uncontrolled or severe chronic inflammation (uveitis), abnormally small eye size (microphthalmus), untreated retinal detachment, untreated chronic glaucoma, cataract caused by rubella virus, abnormal blood vessels on the iris (rubeosis), certain kinds of damaged blood vessels in the retina, and intraocular infections. It is also contraindicated for patients who are pregnant.
     
    The CustomFlex Artificial Iris was approved through a premarket approval application (PMA), which is the most stringent type of device marketing application and generally required for high-risk devices. A PMA approval is primarily based on a determination by the FDA that the PMA contains sufficient valid scientific evidence that provides reasonable assurance that the device is safe and effective for its intended uses.
     
    CustomFlex Artificial Iris was granted Breakthrough Device designation, meaning the FDA provided intensive interaction and guidance to the company on efficient device development, to expedite evidence generation and the agency’s review of the device. To qualify for such designation, a device must provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition, and meet one of the following criteria: the device must represent a breakthrough technology; there must be no approved or cleared alternatives; the device must offer significant advantages over existing approved or cleared alternatives; or the availability of the device is in the best interest of patients.
     
    The FDA granted approval of the CustomFlex Artificial Iris to HumanOptics AG.
    Related Searches
    • development
    • melanoma
    • technology
    • glaucoma
    Suggested For You
    FDA Approves Abbott FDA Approves Abbott's Portico with FlexNav TAVR System
    Indago Announces $10 Million Financing Close and Name Change Indago Announces $10 Million Financing Close and Name Change
    FDA Approves TransMedics FDA Approves TransMedics' OCS Heart System for Donor Hearts
    LifeSignals Inc. Receives FDA Approval for Remote Monitoring Platform LifeSignals Inc. Receives FDA Approval for Remote Monitoring Platform
    Nevro Corp Receives FDA Approval for Senza System Nevro Corp Receives FDA Approval for Senza System
    Receiving FDA Approval in Under One Month Receiving FDA Approval in Under One Month
    FDA Approves AtriCure FDA Approves AtriCure's EPi-Sense System for Persistent Afib
    Expanded FDA Approval for Medtronic Expanded FDA Approval for Medtronic's Arctic Front Cryoablation Catheter
    FDA Clears Neurescue FDA Clears Neurescue's Intelligent Balloon Catheter
    Global Diabetes Care Devices Market to Garner $39.4B by 2027 Global Diabetes Care Devices Market to Garner $39.4B by 2027
    J&J Vision ACUVUE Abiliti Overnight Lenses for Myopia Earn FDA Approval J&J Vision ACUVUE Abiliti Overnight Lenses for Myopia Earn FDA Approval
    FDA Grants Breakthrough Device Status to Epilepsy Treatment System FDA Grants Breakthrough Device Status to Epilepsy Treatment System
    Medtronic Receives FDA Approval for Pipeline Flex Embolization Device with Shield Technology Medtronic Receives FDA Approval for Pipeline Flex Embolization Device with Shield Technology
    Cardiovascular Device Market Expands to Tackle Higher Disease Burden Cardiovascular Device Market Expands to Tackle Higher Disease Burden
    Home Is Where the Heart (Valve) Is Home Is Where the Heart (Valve) Is

    Related Breaking News

    • Cardiovascular
      FDA Approves Abbott

      FDA Approves Abbott's Portico with FlexNav TAVR System

      Self-expanding TAVR valve features intra-annular (within the native valve) leaflets.
      PR Newswire 09.20.21

    • Indago Announces $10 Million Financing Close and Name Change

      Indago Announces $10 Million Financing Close and Name Change

      Lazurite Holdings is developing technology to create the operating room of the future.
      Business Wire 09.15.21

    • Cardiovascular
      FDA Approves TransMedics

      FDA Approves TransMedics' OCS Heart System for Donor Hearts

      Indicated for preservation of DBD (donors after brain death) hearts.
      PR Newswire 09.07.21


    • Patient Monitoring
      LifeSignals Inc. Receives FDA Approval for Remote Monitoring Platform

      LifeSignals Inc. Receives FDA Approval for Remote Monitoring Platform

      The LX1550 Platform can be used by clinicians for the continuous collection of patient physiological data at home and in healthcare settings.
      LifeSignals Inc. 08.05.21

    • Neurological
      Nevro Corp Receives FDA Approval for Senza System

      Nevro Corp Receives FDA Approval for Senza System

      The 10 kHz high frequency spinal cord stimulation therapy is designed for treatment of chronic pain associated with painful diabetic neuropathy.
      Nevro Corp. 07.29.21

    Loading, Please Wait..

    Trending
    • A New Approach To Post-Market Surveillance
    • Diabetes Innovation: MIT Engineers Unveil Implantable Device With Oxygen Factory
    • FDA Clears LiveMetric's Wearable Blood Pressure Monitoring Tech
    • Cochlear Implant Study Underway At Mayo Clinic
    • MPO's Most-Read Stories This Week—Sept. 16
    Breaking News
    • Tessy Plastics Names Stafford Frearson as President
    • HoneyNaps' AI Sleep Disorder Diagnosis Software Earns FDA Nod
    • Biomerics Finishes Expansion of Minnesota Facility
    • MPO's Most-Read Stories This Week—Sept. 23
    • Beckman Coulter Helping Labs Comply With Annex 1 Regulation
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Superior Subtractive Solutions for Machining Medtech
    • Medical Device Industry Experts' Thought on Assembly & Automation
    • Power Trip: A Discussion of Custom Medical Electronics
    • The MDR Transition: An Opportunity for Design Change?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    GOED Releases Sustainability Report for Omega-3s Industry
    ABC’s Journal HerbalGram Celebrates 40th Anniversary
    Curcumin May Be As Effective as PPI for Indigestion
    Coatings World

    Latest Breaking News From Coatings World

    Śnieżka Group Results are Above Expectations in 1H 2023
    ACS Reports Chameleon Inspired Building Coating
    Substrate Wetting Agent Available from BRB International
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Sept. 23
    Beckman Coulter Helping Labs Comply With Annex 1 Regulation
    FDA Clears MeMed BV Direct From Whole Blood
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Eftilagimod Cleared for Clinical Trial Use in the UK
    Veranova Names William Sanders Global VP of Chemical Development Ops
    Chime, Panolos Partner to Advance Multi-specific Therapeutic Proteins
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Investindustrial to Acquire 51% Share of Virospack
    Weekly Recap: J&J Updates Visual Identity, L’Oréal Makes Executive Changes & More
    Hailey Bieber's Rhode Expands Into Makeup
    Happi

    Latest Breaking News From Happi

    SC Johnson’s Guardian Spatial Mosquito Repellent Tool Hits Milestone in Field Testing
    Ulta Beauty’s The Joy Project Address Everyone’s Struggle with Negative Self-Talk
    Natural Products Expo East Tradeshow Closes
    Ink World

    Latest Breaking News From Ink World

    Cooper Watson Acquires Tower Products
    The Durst Group Awarded Eight 2023 PRINTING United Alliance Pinnacle Awards
    Weekly Recap: Wikoff Color, HP, INX VC Top This Week’s Stories
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    PRX Market debuts, Tower Products acquired and more
    Flexo Wash to exhibit at FTA Fall Technical Conference
    Recyclable, deinkable stand-up pouch wins Gold in Germany
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Soft N' Dry Seeks to Expand Private Label Roll Out, Albis Completes Work on Line
    Lenzing Earns EU Ecolabel at Indonesian Plant
    Albis Completes Work On Extra Wide Carding, Blending Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Sept. 23
    Anika Releases RevoMotion Reverse Shoulder Arthroplasty System
    Exactech's Activit-E Polyethylene OK'ed for Vantage Total Ankle
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    HID to Showcase Future-Proof Solutions at GITEX 2023
    Weekly Recap: Mergers and Acquisitions, IEC’s IME Standards Top This Week’s Stories
    EU-Funded Collaboration Hub Aims to Mainstream Printed Electronics

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login